Some for-profit firms have entered into collaborative deals to advance stem cell research, generating new ways to attract investors and launch technologies. One such company is International Stem Cell Corp., which has agreed to work with Novocell to develop a renewable supply of insulin-producing cells for use in diabetes treatment.

Related Summaries